Incyte (INCY) to Announce Earnings on Tuesday

Incyte (NASDAQ:INCY) is expected to announce its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect the company to post earnings of $2.15 per share and revenue of $1.4880 billion for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, July 28, 2026 at 8:00 AM ET.

Incyte (NASDAQ:INCY) last issued its earnings results on Tuesday, April 28th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.38 by $0.43. The business had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.22 billion. Incyte had a return on equity of 26.66% and a net margin of 26.71%.The company’s revenue was up 20.9% compared to the same quarter last year. During the same period last year, the business posted $1.16 EPS. On average, analysts expect Incyte to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Incyte Stock Up 0.8%

Incyte stock opened at $117.67 on Friday. Incyte has a 12 month low of $69.69 and a 12 month high of $119.60. The stock has a fifty day simple moving average of $106.82 and a two-hundred day simple moving average of $101.63. The company has a current ratio of 3.68, a quick ratio of 3.60 and a debt-to-equity ratio of 0.01. The firm has a market cap of $23.51 billion, a price-to-earnings ratio of 16.62, a PEG ratio of 1.06 and a beta of 0.76.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in INCY. Atlas Capital Advisors Inc. purchased a new stake in Incyte in the 4th quarter worth approximately $35,000. MUFG Securities EMEA plc bought a new position in shares of Incyte in the second quarter worth approximately $32,000. CYBER HORNET ETFs LLC purchased a new stake in shares of Incyte in the second quarter worth $33,000. Triumph Capital Management bought a new stake in shares of Incyte during the 4th quarter valued at $63,000. Finally, T. Rowe Price Investment Management Inc. bought a new stake in shares of Incyte during the 4th quarter valued at $65,000. Institutional investors own 96.97% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on INCY. Morgan Stanley boosted their target price on Incyte from $103.00 to $104.00 and gave the stock an “equal weight” rating in a research report on Thursday. Stifel Nicolaus set a $123.00 price objective on shares of Incyte in a report on Tuesday, June 9th. Citigroup restated a “market perform” rating on shares of Incyte in a research report on Wednesday, July 15th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Incyte in a research note on Monday, June 29th. Finally, BMO Capital Markets increased their price target on Incyte from $94.00 to $112.00 and gave the company a “market perform” rating in a report on Monday, July 13th. Eight research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $111.10.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.